Back to Search Start Over

InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma

Authors :
Irene Orlow
Keimya D. Sadeghi
Sharon N. Edmiston
Jessica M. Kenney
Cecilia Lezcano
James S. Wilmott
Anne E. Cust
Richard A. Scolyer
Graham J. Mann
Tim K. Lee
Hazel Burke
Valerie Jakrot
Ping Shang
Peter M. Ferguson
Tawny W. Boyce
Jennifer S. Ko
Peter Ngo
Pauline Funchain
Judy R. Rees
Kelli O’Connell
Honglin Hao
Eloise Parrish
Kathleen Conway
Paul B. Googe
David W. Ollila
Stergios J. Moschos
Eva Hernando
Douglas Hanniford
Diana Argibay
Christopher I. Amos
Jeffrey E. Lee
Iman Osman
Li Luo
Pei-Fen Kuan
Arshi Aurora
Bonnie E. Gould Rothberg
Marcus W. Bosenberg
Meg R. Gerstenblith
Cheryl Thompson
Paul N. Bogner
Ivan P. Gorlov
Sheri L. Holmen
Elise K. Brunsgaard
Yvonne M. Saenger
Ronglai Shen
Venkatraman Seshan
Eduardo Nagore
Marc S. Ernstoff
Klaus J. Busam
Colin B. Begg
Nancy E. Thomas
Marianne Berwick
Publication Year :
2022
Publisher :
Cold Spring Harbor Laboratory, 2022.

Abstract

IntroductionWe are conducting a multicenter study to identify classifiers predictive of disease-specific survival in patients with primary melanomas. Here we delineate the unique aspects, challenges, and best practices for optimizing a study of generally small-sized pigmented tumor samples including primary melanomas of at least 1.05mm from AJTCC TNM stage IIA-IIID patients. This ongoing study will target 1,000 melanomas within the international InterMEL consortium. We also evaluated tissue-derived predictors of extracted nucleic acids’ quality and success in downstream testing.MethodsFollowing a pre-established protocol, participating centers ship formalin-fixed paraffin embedded (FFPE) tissue sections to Memorial Sloan Kettering Cancer Center for the centralized handling, dermatopathology review and histology-guided coextraction of RNA and DNA. Samples are distributed for evaluation of somatic mutations using next gen sequencing (NGS) with the MSK-IMPACT™ assay, methylation-profiling (array), and miRNA expression (Nanostring nCounter).ResultsSufficient material was obtained for screening of miRNA expression in 683/685 (99%) eligible melanomas, methylation in 467 (68%), and somatic mutations in 560 (82%). In 446/685 (65%) cases, aliquots of RNA/DNA were sufficient for testing with all three platforms. Among samples evaluated by the time of this analysis, the mean NGS coverage was 249x, 59 (18.6%) samples had coverage below 100x, and 41/414 (10%) failed methylation QC due to low intensity probes or insufficient Meta-Mixed Interquartile (BMIQ)- and single sample (ss)- Noob normalizations. Six of 683 RNAs (1%) failed Nanostring QC due to the low proportion of probes above the minimum threshold. Age of the FFPE tissue blocks (pConclusionOur experience with many archival tissues demonstrates that with careful management of tissue processing and quality control it is possible to conduct multi-omic studies in a complex multi-institutional setting for investigations involving minute quantities of FFPE tumors, as in studies of early-stage melanoma.

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........f5cf4740f1f23eb14b637fa330695e2a
Full Text :
https://doi.org/10.1101/2022.05.21.22275329